Bromide

Bromide

SCHEMBL2912242

Br.CC[C@H](C)N(C)c1ccc2c(n1)CCNC2

nearest known ligand 0.36

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 6/20 0.36
HTR2B P41595 4/20 0.36
HTR2A P28223 3/20 0.36
CYP3A4 P08684 1/20 0.34
CDK1 P06493 1/20 0.32
CDK4 P11802 1/20 0.32
CDK2 P24941 1/20 0.32
CDK7 P50613 1/20 0.32
CDK9 P50750 1/20 0.32
CDK6 Q00534 1/20 0.32
CDK5 Q00535 1/20 0.32
OGA O60502 2/20 0.31
AR P10275 1/20 0.31
POLB P06746 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL2910613 1.00 HTR2C (0.36) HTR2CHTR2BHTR2ACYP3A4CDK1
SCHEMBL13090227 0.99 HTR2C (0.36) HTR2CHTR2BHTR2ACYP3A4CDK1
SCHEMBL13090224 0.99 HTR2C (0.36) HTR2CHTR2BHTR2ACYP3A4CDK1
SCHEMBL2910741 0.84 F10 (0.35) HTR2CHTR2BHTR2ASMN1; SMN2
SCHEMBL2907176 0.84 F10 (0.35) HTR2CHTR2BHTR2ASMN1; SMN2
Hydrochloric Acid SCHEMBL2908620 0.83 CYP3A4 (0.37) HTR2CHTR2BHTR2ACYP3A4CDK4
Bromide SCHEMBL2109969 0.79 AR (0.32) AR
SCHEMBL2912426 0.78 HTR2C (0.36) HTR2CHTR2BHTR2ACYP3A4CDK4
SCHEMBL16210108 0.78 CYP3A4 (0.41) HTR2CCYP3A4POLBSMN1; SMN2
Hydrochloric Acid SCHEMBL2907934 0.78 HTR2C (0.42) HTR2CHTR2BHTR2ACYP3A4POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2789338-A2 Condensed pyridine derivate and use thereof Takeda Pharmaceutical Company Limited (JP) 2014-10-15 EP disclosed
US-20100266504-A1 CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-10-21 US disclosed
EP-2216023-A1 CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-08-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100266504-A1 CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF HTR2C, HTR5A, HTR3C HTR2C 1/4885HTR2B 7/4885HTR2A 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.